Although no studies have explicitly compared the difference in IDH1 status between STR and LTR patients, Weller et al. (9) made a survival analysis for 286 patients with newly diagnosed GBM; they found that IDH1 mutation had a relationship with prolonged PFS; their result was indirectly consistent with our finding, suggesting that IDH1 wild type was an independent short-term recurrence risk factor for glioma patients to some extent. The gene discussed is IDH1; the disease is glioma.